February 10, 2011 – A new bill introduced to the U.S. Senate aims to promote sustainable, domestic production of the medical isotope molybdenum-99 (Mo-99). The bill, also known as the American Medical Isotopes Production Act of 2011, was introduced by Sen. Jeff Bingaman (D-N.M.) and Sen. Lisa Murkowski (R-Ark.).

Bingaman is chair of the Senate Committee on Energy and Natural Resources.

Mo-99 is an isotope that decays to technetium-99m (Tc-99m), which is used in more than 16.7 million procedures in the United States each year. Tc-99m is utilized in the detection of heart disease, detection and staging of cancer, detection of thyroid disease, study of brain and kidney function, and imaging of stress fractures.

There are currently only six foreign producers of Mo-99 approved by the U.S. Food and Drug Administration (FDA) to import it into the United States. No domestic facilities exist that are dedicated to the production of Mo-99 for medical uses. Aging foreign reactors regularly experience significant ongoing maintenance issues, frequently causing these reactors to go off-line. In 2009-2010, the Unites States experienced a shortage of Mo-99, which led to the disruption or delay of nuclear medicine procedures for an estimated 50,000 patients each day.

"In order to ensure that our patients can receive the best medical care, it’s essential that a reliable supply of Mo-99 be available in the United States," said Robert Atcher, chair of SNM’s Government Relations Committee. "The best way for that to be achieved is by developing production facilities for Mo-99 domestically."

The American Medical Isotopes Production Act seeks to establish a technology-neutral program to support the production of Mo-99 for medical uses in the United States by nonfederal entities. The bill also calls for the United States to condition and phase out the export of highly enriched uranium for the production of medical isotopes over a period of seven years.

A bill is expected to be introduced in the House of Representatives in coming weeks.

For more information: www.snm.org


Related Content

News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...

Time July 25, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | ASTRO

June 21, 2024 — The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search ...

Time June 21, 2024
arrow
News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | SNMMI

June 13, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted more than 8,000 physicians ...

Time June 13, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
News | Radiology Business

June 12, 2024 — Cathy Sue Cutler, PhD, FSNMMI, chair of the Isotope Research and Production Department at Brookhaven ...

Time June 12, 2024
arrow
News | SPECT-CT

June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac ...

Time June 11, 2024
arrow
Subscribe Now